Premium
Characterization of the T‐ and B‐cell immune response to a new recombinant pre‐S1, pre‐S2 and SHBs antigen containing hepatitis B vaccine (Hepagene™); evidence for superior anti‐SHBs antibody induction in responder mice
Author(s) -
Jones C. D.,
Page M.,
Bacon A.,
Cahill E.,
Bentley M.,
Chatfield S. N.
Publication year - 1998
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.1998.0050s2005.x
Subject(s) - virology , immune system , recombinant dna , antigen , immune escape , biology , antibody , immunology , gene , genetics
Hepagene™ is a novel recombinant particle consisting of the pre‐S1, pre‐S2 and small surface (SHBs) antigens (Ag) of the hepatitis B virus (HBV) and is adjuvanted with alhydrogel in the final formulation. It has been primarily developed to enhance anti‐SHBs antibody titres in inadequate responders, to conventional SHBsAg vaccines. Since non‐compliance is also a problem with existing HBV vaccine schedules, the ability to accelerate current immunization regimens to provide more rapid protection has also been an important objective. Here we describe the T‐ and B‐cell responses to Hepagene™ in two strains of responder mouse (BALB/c and SWR/J).